Kiniksa Pharmaceuticals Ltd (KNSA) - Total Assets
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) holds total assets worth $825.28 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Kiniksa Pharmaceuticals Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Kiniksa Pharmaceuticals Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Kiniksa Pharmaceuticals Ltd for net asset value and shareholders' equity analysis.
Kiniksa Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Kiniksa Pharmaceuticals Ltd's total assets of $825.28 Million consist of 69.0% current assets and 31.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.7% |
| Accounts Receivable | $15.59 Million | 2.0% |
| Inventory | $54.90 Million | 7.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.25 Million | 2.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KNSA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kiniksa Pharmaceuticals Ltd's current assets represent 69.0% of total assets in 2025, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2025, down from 99.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 7.2% of total assets.
Kiniksa Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Kiniksa Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Almirall S.A.
MC:ALM
|
Spain | €2.36 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
USA | $1.44 Billion |
|
North China Pharmaceutical Co Ltd
SHG:600812
|
China | CN¥21.45 Billion |
Kiniksa Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.79 | 3.66 | 6.31 |
| Quick Ratio | 3.33 | 3.43 | 6.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $437.56 Million | $258.64 Million | $206.03 Million |
Kiniksa Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Kiniksa Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.23 |
| Latest Market Cap to Assets Ratio | 3.79 |
| Asset Growth Rate (YoY) | 31.5% |
| Total Assets | $763.63 Million |
| Market Capitalization | $2.90 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kiniksa Pharmaceuticals Ltd's assets at a significant premium (3.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kiniksa Pharmaceuticals Ltd's assets grew by 31.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual total assets of Kiniksa Pharmaceuticals Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $763.63 Million | +31.54% |
| 2024-12-31 | $580.55 Million | +10.30% |
| 2023-12-31 | $526.32 Million | +14.50% |
| 2022-12-31 | $459.67 Million | +97.45% |
| 2021-12-31 | $232.80 Million | -33.38% |
| 2020-12-31 | $349.46 Million | +37.30% |
| 2019-12-31 | $254.53 Million | -20.94% |
| 2018-12-31 | $321.96 Million | +577.94% |
| 2017-12-31 | $47.49 Million | -15.89% |
| 2016-12-31 | $56.47 Million | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more